Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBAY CymaBay Therapeutics	$32.48	$32.44	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
IRWD Ironwood Pharmaceuticals	$0.59 -4.9%	$0.92	$0.53 ▼ $7.11	$95.86M	0.37	2.57 million shs	1.40 million shs
PTCT PTC Therapeutics	$47.28 -1.2%	$46.80	$28.72 ▼ $58.38	$3.75B	0.52	857,435 shs	717,143 shs
RCKT Rocket Pharmaceuticals	$2.48 +6.4%	$6.44	$2.19 ▼ $26.98	$264.83M	1.02	1.80 million shs	20.90 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBAY CymaBay Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
IRWD Ironwood Pharmaceuticals	-4.85%	+0.58%	-38.96%	-63.43%	-89.93%
PTCT PTC Therapeutics	-1.21%	+2.32%	-4.98%	-6.51%	+29.64%
RCKT Rocket Pharmaceuticals	+6.44%	-62.37%	-65.36%	-73.62%	-88.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	4.6921 of 5 stars	4.1	4.0	0.0	3.4	3.7	0.8	1.9
PTCT PTC Therapeutics	4.2247 of 5 stars	4.3	3.0	0.0	4.4	2.9	0.8	0.0
RCKT Rocket Pharmaceuticals	4.9282 of 5 stars	4.4	3.0	0.0	4.7	3.1	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBAY CymaBay Therapeutics	0.00	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	2.13	Hold	$4.78	707.45% Upside
PTCT PTC Therapeutics	2.64	Moderate Buy	$63.75	34.84% Upside
RCKT Rocket Pharmaceuticals	2.47	Hold	$22.46	805.71% Upside

Current Analyst Ratings Breakdown

Latest PTCT, RCKT, IRWD, and CBAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00
5/28/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $17.00
5/28/2025	RCKT Rocket Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/27/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$68.00 ➝ $74.00
5/27/2025	RCKT Rocket Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
IRWD Ironwood Pharmaceuticals	$317.68M	0.30	N/A	N/A	($2.21) per share	-0.27
PTCT PTC Therapeutics	$1.77B	2.11	$2.27 per share	20.80	($10.85) per share	-4.36
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	N/A
IRWD Ironwood Pharmaceuticals	-$1.00B	-$0.20	N/A	2.37	N/A	-0.65%	-0.96%	0.74%	8/14/2025 (Estimated)
PTCT PTC Therapeutics	-$626.60M	$6.51	N/A	N/A	N/A	-50.32%	N/A	-16.44%	8/14/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)

Latest PTCT, RCKT, IRWD, and CBAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/7/2025	Q1 2025	IRWD Ironwood Pharmaceuticals	-$0.05	-$0.14	-$0.09	-$0.23	$67.02 million	$41.14 million
5/6/2025	Q1 2025	PTCT PTC Therapeutics	$0.85	$10.04	+$9.19	N/A	$437.16 million	$1.18 billion
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
IRWD Ironwood Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBAY CymaBay Therapeutics	N/A	10.96	10.96
IRWD Ironwood Pharmaceuticals	N/A	3.62	3.62
PTCT PTC Therapeutics	N/A	2.10	2.04
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBAY CymaBay Therapeutics	95.03%
IRWD Ironwood Pharmaceuticals	N/A
PTCT PTC Therapeutics	N/A
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
CBAY CymaBay Therapeutics	7.00%
IRWD Ironwood Pharmaceuticals	12.90%
PTCT PTC Therapeutics	5.50%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
IRWD Ironwood Pharmaceuticals	220	161.82 million	139.38 million	Optionable
PTCT PTC Therapeutics	1,410	79.26 million	72.88 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

PTCT, RCKT, IRWD, and CBAY Headlines

Recent News About These Companies

Rocket Pharmaceuticals (NASDAQ:RCKT) Reaches New 12-Month Low - Should You Sell?

May 29 at 6:33 AM | marketbeat.com

Bank of America Cuts Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target to $9.00

May 29 at 3:41 AM | americanbankingnews.com

Rocket Pharmaceuticals' (RCKT) "Hold" Rating Reiterated at Jefferies Financial Group

May 29 at 2:09 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Earns Equal Weight Rating from Morgan Stanley

May 29 at 2:09 AM | americanbankingnews.com

Rocket Pharmaceuticals' (RCKT) Hold Rating Reiterated at Needham & Company LLC

May 29 at 1:37 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Receives Consensus Rating of "Moderate Buy" from Brokerages

May 29 at 1:34 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

May 28 at 6:25 PM | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Connect

May 28 at 3:15 PM | accessnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to "Hold" at TD Cowen

May 28 at 12:18 PM | marketbeat.com

RCKT Stock Tanks on Patient Death in Danon Disease Study

May 28 at 12:11 PM | zacks.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by Needham & Company LLC

May 28 at 11:29 AM | marketbeat.com

These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

May 28 at 10:41 AM | benzinga.com

Rocket Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RCKT)

May 28 at 10:38 AM | marketbeat.com

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease

May 28 at 5:39 AM | pharmabiz.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives "Hold" Rating from TD Cowen

May 28 at 2:41 AM | americanbankingnews.com

Investors Purchase High Volume of Rocket Pharmaceuticals Call Options (NASDAQ:RCKT)

May 28 at 1:06 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death

May 27 at 9:28 PM | insidermonkey.com

Danon Disease Patient Dies in Rocket Gene Therapy Trial

May 27 at 7:37 PM | genengnews.com

Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold

May 27 at 12:00 PM | benzinga.com

Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death

May 27 at 10:37 AM | proactiveinvestors.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 5.6% - Time to Sell?

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PTCT, RCKT, IRWD, and CBAY Company Descriptions

CymaBay Therapeutics NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Ironwood Pharmaceuticals NASDAQ:IRWD

$0.59 -0.03 (-4.85%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$0.60 +0.01 (+1.62%)

As of 04:09 AM Eastern

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

PTC Therapeutics NASDAQ:PTCT

$47.28 -0.58 (-1.21%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$48.50 +1.22 (+2.58%)

As of 06:25 AM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.48 +0.15 (+6.44%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$2.52 +0.04 (+1.77%)

As of 06:33 AM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time